SARS-CoV-2

QBI and Director Krogan’s COVID and infectious disease efforts continue to make waves

Thu Sep 21, 2023

Research!America President and CEO Mary Woolley (left) with QBI Director Nevan Krogan, PhD (center), and Pfizer Senior Vice President and Head of Vaccine Research and Development Annaliesa Anderson, PhD (right).

QBI publishes breakthrough on COVID-19 variants; Nevan Krogan recognized as trailblazer.

UCSF Quantitative Biosciences Institute and Institut Pasteur form center to fight infectious disease

Fri Oct 28, 2022

QBI Director Nevan Krogan, PhD, and Professor Stewart Cole, PhD, president of the Institut Pasteur, sign the memorandum of understanding for the new Institut Pasteur-UCSF QBI Center of Excellence in Emerging Infectious Diseases at a ceremony in the historic Musée Pasteur in Paris, France.

QBI Director Krogan receives the Legion of Honor, France’s highest award

QBI continues research efforts to stave off future surges of COVID-19

Wed Jun 30, 2021

NIAID/NIH

A cell (blue) heavily infected with SARS-CoV-2 virus particles (green), isolated from a patient sample.

Research into SARS-CoV-2 variants and potential therapies pushes forward

A reliable test for COVID-19 immunity

Wed Apr 28, 2021

NIAID/NIH

SARS-CoV-2 particles (magenta) emerging from the surface of cells cultured in the lab.

The Wells Lab developed an efficient test for SARS-CoV-2 antibodies

Cancer drug stops SARS-CoV-2 in the lab

Thu Feb 11, 2021

PharmaMar

Aplidin is extracted from Aplidium albicans, a sea squirt found off the coast of Spain.

“If you get a drug that targets a human protein, it would be incredibly hard for the virus to mutate away from being reliant on it,” said Nevan Krogan, the director of QBI.

Jamming the gears of a deadly virus

Fri Nov 13, 2020

NIH

A 3D printed model of a SARS-CoV-2 viral particle (blue) dotted with the spike protein (red) that enables the virus to infect human cells. The spike protein is the target of research efforts to prevent and treat COVID-19.